原位肝移植受者对不同SARS-CoV-2疫苗的体液应答
该研究纳入2021年2月至9月的187名参与者(133例原位肝移植受者、54名健康对照),在完成全程疫苗接种15天后检测SARS-CoV-2 IgG。肝移植受者的血清学应答低于对照(中位数549 AU/mL vs 3450 AU/mL,p=0.001)。接种BNT162b2疫苗与较高的血清学应答相关。
要点
- 肝移植受者接种COVID-19疫苗后血清学应答低于健康对照。
- BNT162b2接种与较高的血清学应答相关。
- 泼尼松使用(相较其他免疫抑制剂)降低血清学应答。
核心结论
- 原位肝移植受者对COVID-19疫苗的血清学应答低于健康对照。
- BNT162b2疫苗与较高的血清学应答相关。
研究设计与样本
- 研究纳入2021年2月至9月的参与者,肝移植患者未适用优先接种轮次安排,对照为其他方面健康的人群。
- 共纳入187名参与者(133例原位肝移植受者、54名对照,中位年龄60岁,58.8%为女性),74.3%至少有一种合并症。
- 在完成全程疫苗剂量15天后采血,使用DiaSorin Liaison XL平台和Abbott SARS-COV-2 IgG II Quant按厂商说明进行分析。
主要发现
- 肝移植受者的血清学应答低于对照(中位数549 AU/mL vs 3450 AU/mL,p=0.001)。
- 肝移植受者中阳性体液应答率:BNT162b2为89.2%,ChAdOx1 nCOV-19为60%,CoronaVac为76.9%,Ad5-nCov为55.6%,Gam-COVID-Vac为68.2%,mRNA-1273为100%。
- 对照中血清学应答率为100%,但Cansino为75%。
- 多变量模型中,个人COVID-19病史和BNT162b2接种与血清学应答相关,而使用泼尼松(相较其他免疫抑制剂)降低该应答。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The safety and efficacy data of the different types of available vaccines is still needed. The goal of the present analysis was to evaluate the humoral response to the COVID-19 vaccines in orthotopic liver transplant (OLT) recipients. METHODS: Participants were included from February to September 2021. No prioritized vaccination roll call applied for OLT patients. Controls were otherwise healthy people. Blood samples were drawn after 15 days of the complete vaccine doses. The samples were analyzed according to the manufacturer's instructions using the Liaison XL platform from DiaSorin (DiaSorin S.p.A., Italy), and SARS-COV-2 IgG II Quant (Abbott Diagnostics, IL, USA). RESULTS: A total of 187 participants (133 OLT, 54 controls, median age: 60 years, 58.8% women) were included for the analysis; 74.3% had at least one comorbidity. The serologic response in OLT patients was lower than in controls (median 549 AU/mL vs. 3450 AU/mL, respectively; p = 0.001). A positive humoral response was found in 133 OLT individuals: 89.2% with BNT162b2 (Pfizer-BioNTech), 60% ChAdOx1 nCOV-19 (Oxford-AstraZeneca), 76.9% with CoronaVac (Sinovac, Life Sciences, China), 55.6% Ad5-nCov (Cansino, Biologics), 68.2% Gam-COVID-Vac (Sputnik V) and 100% with mRNA-1273. In controls the serological response was 100%, except for Cansino (75%). In a multivariable model, personal history of COVID-19 and BNT162b2 inoculation were associated with the serologic response, while the use of prednisone (vs. other immunosuppressants) reduced this response. CONCLUSION: The serologic response to COVID-19 vaccines in OLT patients is lower than in healthy controls. The BNT162b2 vaccine was associated with a higher serologic response.
引用
- Toapanta-Yanchapaxi L, Chiquete E, Ávila-Rojo E, et al. Humoral response to different SARS-CoV-2 vaccines in orthotopic liver transplant recipients. Vaccine. 2022. PMID: 36028456. doi:10.1016/j.vaccine.2022.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。